Cosentyx

Moderate to severe plaque psoriasis in adults, adolescents & childn from the age of 6 yr who are candidates for systemic therapy. Active moderate to severe hidradenitis suppurativa (acne inversa) in adults w/ inadequate response to conventional systemic HS therapy. Alone or in combination w/ MTX for active psoriatic arthritis in adults w/ inadequate response to previous DMARD therapy. Active ankylosing spondylitis in adults w/ inadequate response to conventional therapy. Active non-radiographic axial spondyloarthritis w/ objective signs of inflammation as indicated by elevated C-reactive protein &/or MRI evidence in adults w/ inadequate response to NSAIDs. Alone or in combination w/ MTX for active enthesitis-related arthritis in patients ≥6 yr whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. Alone or in combination w/ MTX for active juvenile psoriatic arthritis in patients ≥6 yr whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

SC Adult plaque psoriasis 300 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Based on clinical response, maintenance dose of 300 mg every 2 wk may provide additional benefit for patients weighing ≥90 kg. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Paed plaque psoriasis Recommended dose is based on body wt w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Patient weighing ≥50 kg 150 mg, may be increased to 300 mg, 25 to <50 kg 75 mg, <25 kg 75 mg. Hidradenitis suppurativa 300 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Based on clinical response, maintenance dose can be increased to 300 mg every 2 wk. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Psoriatic arthritis Patient w/ concomitant moderate to severe plaque psoriasis 300 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Based on clinical response, maintenance dose of 300 mg every 2 wk may provide additional benefit for patients weighing ≥90 kg. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Anti-TNFα inadequate responder 300 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Other patient 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Based on clinical response, dose can be increased to 300 mg. Ankylosing spondylitis 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Based on clinical response, dose can be increased to 300 mg. Each 300-mg dose is given as 1 SC inj of 300 mg or as 2 SC inj of 150 mg. Non-radiographic axial spondyloarthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Enthesitis-related arthritis & juvenile psoriatic arthritis Recommended dose is based on body wt & administered at wk 0, 1, 2, 3, & 4, followed by mthly maintenance dosing. Patient weighing ≥50 kg 150 mg, <50 kg 75 mg.

Hypersensitivity. Clinically important, active infection eg, active TB.

Discontinue immediately in case of anaphylactic or other serious allergic reactions. Areas of the skin that show psoriasis should be avoided as inj sites. Potential to increase risk of infections. Caution in patients w/ chronic infection or history of recurrent infection. Closely monitor patient if serious infection develops & do not administer treatment until infection resolves. Consider anti-TB therapy prior to secukinumab initiation in patients w/ latent TB. Reports of new or exacerbations of inflammatory bowel disease (including Crohn's disease & ulcerative colitis). Not recommended in patients w/ inflammatory bowel disease. Concurrent administration w/ live vaccines. Concomitant immunosuppressive therapy eg, biologics, or phototherapy. Latex-sensitive individuals (150 mg/mL pre-filled pen only). Has not been studied in patients w/ renal/hepatic impairment. Women of childbearing potential should use effective contraception during treatment & for at least 20 wk after treatment. Preferable to avoid use during pregnancy. Discontinue breast-feeding during treatment & up to 20 wk after treatment, or discontinue Cosentyx therapy. Safety & efficacy have not been established in childn <6 yr w/ plaque psoriasis, enthesitis-related arthritis, & juvenile psoriatic arthritis. Safety & efficacy have not yet been established in childn <18 yr in other indications.

URTI. Oral herpes; headache; rhinorrhoea; diarrhoea, nausea; fatigue.

Should not be given w/ live vaccines.

Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations

L04AC10 - secukinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.

P₁S₁S₃